Genentech/Xoma Raptiva Promotions Likely To Focus On Dosing Convenience
Executive Summary
Genentech/Xoma plan to differentiate the psoriasis agent Raptiva from other biologics by highlighting Raptiva's dosing convenience
You may also be interested in...
Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis
Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications
Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis
Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive